Antibody

Advanced Map of Human Blood Stem Cells Could Guide Highly Targeted Leukemia Care

Retrieved on: 
Thursday, March 21, 2024
Glycophorin A, B cell, Gene, Flow cytometry, Gene expression, Cell, AML, Mechanics, Patient, Biomarker, Research, RNA, Leukemia, Doctor of Philosophy, AUC, CD326, Antibody, Machine learning, Game theory, Blood, Hematology, Bone marrow, Atlas, Vaccine

CINCINNATI , March 21, 2024 /PRNewswire/ -- Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at Cincinnati Children's has published the world's most detailed "atlas" of the many types of stem cells and early progenitors involved in producing human blood from diverse donors.

Key Points: 
  • The team has identified more than 80 distinct subsets of hematopoietic stem and progenitor cells (HSPCs) – early-stage cells that kick off production of mature red cells, white cells and other elements of our complex blood system.
  • Among the team's key findings:
    Mixing a new "cocktail" of 132 antibodies that can target surface proteins on HSPCs and related cells.
  • Testing demonstrated that the new mix outperforms commercial products for profiling human bone marrow cells.
  • One of the most immediate potential applications of the new stem cell atlas centers on how treatment centers monitor patients receiving therapies for leukemia.

International Harrington Prize Awarded to Dr. Arlene Sharpe

Retrieved on: 
Tuesday, March 19, 2024
LDL, Human papillomavirus infection, Patient, DSM-IV codes, Lecture, National Cancer Institute, Harvard University, Creativity, AAP, PD-1, Massachusetts General Hospital, Science, Diabetes, Marfan syndrome, All India Mahila Congress, Immunology, AUC, NIH, Cancer, Nivolumab, Immune system, Biochemistry, Harvard Medical School, Cervical cancer, Research, University, Antibody, ASCI, FDA, Mount Sinai Hospital, Sickle cell disease, University of Pennsylvania, PCSK9, COVID-19, Doctor of Philosophy, Biology, Kidney, Thalassemia, Johns Hopkins University, Society, Division, Leptin, Pharmaceutical industry

CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School. The award recognizes her breakthrough discoveries in immune regulation, which have established foundational principles in immunology and led to new cancer therapies that act by boosting the immune response to cancer.

Key Points: 
  • CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.
  • Her work helped identify key pathways that restrain the activity of T lymphocytes (immune cells) to fight cancer.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers globally before selecting the 2024 Harrington Prize recipient.
  • 2023: Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their groundbreaking translational research to restore sight in inherited genetic diseases.

BLACK SKULL LAUNCHES AT A FAIR IN CALIFORNIA A POST-WORKOUT WITH EXCLUSIVE SALE ON AMAZON

Retrieved on: 
Friday, March 15, 2024
Health, GROW, Stevia, University, Hormone, Islam, Sport, Amazon, Lactose, Antibody, GMO, Colostrum, GDS, Hypertrophy, Quality of life, Jews, Diet, Investment, Water, Oligosaccharide, WHEY, Multimedia, BLACK, Soil, Food safety, Chocolate, Allergen, Dairy

SÃO PAULO, March 14, 2024 /PRNewswire/ -- BLACK SKULL (www.blackskullusa.com), a brand from Grow Dietary Supplements Labs USA (GDS), a leader in the hardcore nutrition segment in Brazil, participates in the largest fair in the world in the natural sector, the Natural Products Expo West, which takes place from March 12th to 16th, in Anaheim, California – USA. The brand will present its newest launch, WHEY GRASS FED, the first post-workout supplement that has 19g of high biological value protein and 1g of Bovine Colostrum, which will be sold exclusively on the AMAZON platform, initially for the North American market.

Key Points: 
  • The supplement is Halal and Kosher certified and will be presented at Natural Products Expo West.
  • Colostrum is composed of a powerful combination of bioactives (immunoglobulins, immune modulators and oligosaccharides), which support immunological, respiratory and intestinal health.
  • The product arrives in sustainable 900-gram packaging, with freeze-dried natural smell from the Amazon, such as Guaraná with Açaí and Chocolate with Cupuaçu.
  • "In addition to contributing to the health of consumers, WHEY GRASS FED will help fruit producer cooperatives in the Amazon and riverside families.

Calder Biosciences Inc. Publishes Next-Generation Vaccine Technology in Nature Communications

Retrieved on: 
Thursday, March 14, 2024
Health, Infection, GSK, Ageing, 3D, MD, RSV, Protein engineering, Antibody, Licensure, Respiratory syncytial virus, Vaccination, CSO, Vaccine, Paper, Animal, Nature Communications

BROOKLYN, N.Y., March 14, 2024 /PRNewswire/ -- Calder Biosciences, Inc ., a next-generation vaccine company, has been published in a Nature Communications article ( https://www.nature.com/articles/s41467-024-46295-8 ) that debuts and validates the application of Calder's '3D Vaxlock' platform technology.

Key Points: 
  • BROOKLYN, N.Y., March 14, 2024 /PRNewswire/ -- Calder Biosciences, Inc ., a next-generation vaccine company, has been published in a Nature Communications article ( https://www.nature.com/articles/s41467-024-46295-8 ) that debuts and validates the application of Calder's '3D Vaxlock' platform technology.
  • Application of the technology not only dramatically improves potency, but also improves shelf-life of the vaccine at refrigerated temperatures that will facilitate distribution and delivery.
  • In the Nature Communications manuscript, Calder demonstrates that a high dose of their RSV vaccine achieves responses in aged, immunosenescent animals equivalent to responses in the young animal control group.
  • Calder also plans to apply its technology more generally in protein engineering, imparting thermostability as needed to additional subunit vaccines, biologics, or other targets.

Rapid Novor and MAbSilico Partner for World's First AI-Guided Epitope Mapping Service for Antibodies

Retrieved on: 
Wednesday, March 13, 2024
Dicarboxylic acid, Algorithm, Intelligence, Epitope, Deuterium, AI, Proteomics, Marketing, Antibody, Artificial intelligence, Therapy, CSO, Antigen, Vaccine

KITCHENER, ON, March 13, 2024 /PRNewswire-PRWeb/ -- Rapid Novor Inc and MAbSilico announced that they have partnered to provide the world's first AI-driven HDX-MS epitope mapping service for antibody development. By seamlessly integrating experimental data from HDX-MS with predictive analytics derived from AI-driven computational modeling, researchers can gain a comprehensive understanding of antibody structure, dynamics, and interactions with unparalleled precision and speed.

Key Points: 
  • Rapid Novor and MAbSilico partner to provide the world's first comprehensive AI-guided epitope mapping service.
  • KITCHENER, ON, March 13, 2024 /PRNewswire-PRWeb/ -- Rapid Novor Inc and MAbSilico announced that they have partnered to provide the world's first AI-driven HDX-MS epitope mapping service for antibody development.
  • "Artificial intelligence promises a turning point in antibody drug discovery and development," states Iain Rogers, VP Sales and Marketing at Rapid Novor.
  • "This AI-integrated approach enables rapid screening of antibodies from extensive candidate pools," adds Zak Omahdi, Scientific Business Developer at MAbSilico.

Immunovia announces updated financial calendar

Retrieved on: 
Tuesday, March 12, 2024
Risk, Protein, Patient, Nasdaq Stockholm, Pancreatic cancer, Antibody, Pharmaceutical industry

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.

Key Points: 
  • Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.
  • Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
  • Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
  • The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia announces updated financial calendar

Retrieved on: 
Tuesday, March 12, 2024
Risk, Protein, Patient, Nasdaq Stockholm, Pancreatic cancer, Antibody, Pharmaceutical industry

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.

Key Points: 
  • Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection.
  • Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
  • Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
  • The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

Retrieved on: 
Monday, March 11, 2024
Diagnosis, Brain, Conference, Lecanemab, Disease, Incidence, Alpha-synuclein, Eisai, Patient, CAA, ARIA, DSM-IV codes, Antibody, Safety, Clarity, Pharmaceutical industry

BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.

Key Points: 
  • BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.
  • Lecanemab was designed to preferentially bind soluble (protofibrils), as well as insoluble Aβ aggregates (fibrils), to reduce both Aβ protofibrils and Aβ plaques in the brain.
  • The difference in binding to CAA[1] was presented, with lecanemab having lower binding to CAA than most other antibodies.
  • This could explain the difference in the adverse event ARIA[2] seen between different antibodies, with lecanemab showing relatively low incidence of ARIA.

Autolus Therapeutics announces publication in Blood Cancer Journal

Retrieved on: 
Monday, March 11, 2024
TRBC1, Antibody, Mayo Clinic, Lymphoid leukemia, Thermo Fisher Scientific, TRBC, Bone marrow, Flow cytometry, Vaccine

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.’ 1

Key Points: 
  • LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.’ 1
    Diagnosing leukemic T-cell malignancies poses challenges due to their resemblance to reactive T-cells.
  • In the paper published by Pedro Horna of Mayo Clinic in collaboration with Autolus, the authors introduce a unique approach for identifying T-cell neoplasms by flow cytometry1.
  • This method adopts the recently described monoclonal antibodies targeting TRBC1 and TRBC22, 3, to assess for TRBC-restriction as a surrogate of clonality.
  • The strategy mirrors the routine and broadly adopted analysis of kappa and lambda immunoglobulin chain restriction for the identification of B-cell malignancies.

Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference

Retrieved on: 
Monday, March 11, 2024
Aggregation, Enzyme, Pathology, Neuron, Treatment, Skill, Synuclein, ELISA, Neurodegenerative disease, Conference, Antibody, IHC, Therapy, Death, Patient, Synucleinopathy, Three-body problem, DSF, SPR, Brain

BRISBANE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases and their substrates, a new class of enzymes discovered in-house that are implicated in a broad variety of diseases, today announced an abstract titled “Unveiling of a Novel Therapeutic Antibody Targeting Nitrated Alpha Synuclein for the Treatment of Parkinson’s Disease” was featured in an oral presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference taking place in Lisbon, Portugal from March 5-9, 2024. The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies. Nitrase’s antibody demonstrated both high affinity and selectivity for nitrated synuclein, and it demonstrated the ability to significantly reduce PD progression in in vitro and in vivo PD models.

Key Points: 
  • The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies.
  • A hallmark of PD pathology is the presence of Lewy Bodies and Lewy Neurites, which have been found to include an accumulation of nitrated α-synuclein.
  • It has been established in published studies that PD pathology spreads between brain regions along neural circuitry through extracellular aggregated α-synuclein.
  • Additionally, our antibody demonstrated superiority in a preclinical efficacy evaluation against the parental antibody of  prasinezumab, which targets non-nitrated α-synuclein.